Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer.

Journal of the American College of Surgeons - 1 Jun 2018

Erinjeri Neeta J, Nicolson Norman G, Deyholos Christine, Korah Reju, Carling Tobias

Abstract excerpt

BACKGROUND: Thyroid cancer is the most common endocrine malignancy, with continuously increasing incidence. Follicular thyroid cancer (FTC) accounts for approximately 10% to 15% of these cases and is known to be associated with several gene mutations. The purpose of this study was to identify novel therapeutic targets in FTC using whole-exome sequencing (WES) and bioinformatics analysis. STUDY DESIGN: Whole-exome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Exome Sequencing

Share to CDK1 gene

Share to Mutation

Share to Precision Medicine

Share to Signal Transduction

Source

Identifiers

PMID: 29571661
DOI: 10.1016/j.jamcollsurg.2018.01.059

Genes

AHCTF1
CDC27
CDK1
FRG1
MUC20
NCOR1
PABPC1
PABPC3
PRSS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-Exome Sequencing Identifies Two Discrete Druggable Signaling Pathways in Follicular Thyroid Cancer.PMID 29571661Read ↗

Characterization of the genomic alterations in poorly differentiated thyroid cancer.Semantic proximity Read ↗

Somatic mutation profiling of follicular thyroid cancer by next generation sequencing.Semantic proximity Read ↗

Comprehensive Genetic Analysis of Follicular Thyroid Carcinoma Predicts Prognosis Independent of Histology.Semantic proximity Read ↗

Detection of Molecular Alterations in Taiwanese Patients with Medullary Thyroid Cancer Using Whole-Exome Sequencing.Semantic proximity Read ↗

Molecular Signature Expands the Landscape of Driver Negative Thyroid CancersSemantic proximity Read ↗

Genomic alterations in thyroid cancer: biological and clinical insights.Semantic proximity Read ↗

Single-cohort next-generation sequencing analysis of 713 anaplastic thyroid carcinomas: unreported gene alterations and actionable targets.Semantic proximity Read ↗

The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.Semantic proximity Read ↗

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

An integrated analysis of cancer genes in thyroid cancer.Semantic proximity Read ↗

Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling PathwaysSemantic proximity Read ↗

Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.